why choose us

First received: November 02, 2022

Clinical Trial: ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

Study Status: Completed

Recruit Status: RECRUITING

Condition: B-cell Lymphoma

Study Type: INTERVENTIONAL


Official Title: A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic CD20-conjugated Gamma Delta T-cell Therapy, in Adult Subjects With Relapsed/Refractory CD20-expressing B-c

Brief Summary: ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of CD20-expressing B-cell malignancies.The ACE1831-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, and efficacy of ACE1831 in patients with CD20-expressing Non-Hodgkin lymphoma.

Read more